Talimogene Laherparepvec for Treating Unresectable Metastatic Melanoma (TA410)

Technology Appraisal Guidance No. 410

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Talimogene laherparepvec is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if:

  • treatment with systemically administered immunotherapies is not suitable and
  • the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.

1.2 This guidance is not intended to affect the position of patients whose treatment with talimogene laherparepvec was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta410

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

    Talimogene laherparepvec for treating unresectable metastatic melanoma

    Issue Date: September 2016

    Have you registered with us yet?

    Register now to enjoy more articles and free email bulletins

    Already registered?
    Sign in

    More from MIMS

    Further monthly injectable migraine prophylactic launched

    Further monthly injectable migraine prophylactic launched

    With the launch of Emgality (galcanezumab), prescribers...

    Vitamin D3 Supplements

    Formulations and indications of colecalciferol preparations.

    Avoid gout drug in patients with major cardiovascular conditions, says MHRA

    Avoid gout drug in patients with major cardiovascular conditions, says MHRA

    Treatment with febuxostat (Adenuric) should be avoided...

    Drug shortages - live tracker

    Drug shortages - live tracker

    Added: Colestid Orange. Use our constantly updated...